Clearline Capital’s Evolent Health EVH Stock Holding History

Clearline Capital’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-37,001	Closed	-$659K	–	54
2017 Q3	$659K	Buy	+37,001	New	+$762K	0.48%	30

Other funds holding EVH

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return

Clearline Capital's EVH Position: Q4 2017 in Review

Clearline Capital sold out of Evolent Health (EVH) in Q4 2017, closing a stake of 37,001 shares — an estimated $659K sold.

Clearline Capital first reported a position in EVH in Q3 2017 and held it in 1 quarter. The position peaked at $659K in Q3 2017. 156 funds tracked by Wall St. Rank hold EVH as of Q4 2017.

Clearline Capital reported no remaining Evolent Health position as of Q4 2017 after selling out during the quarter.
Clearline Capital sold 37,001 Evolent Health shares in Q4 2017, an estimated $659K.
Clearline Capital first reported a position in Evolent Health in Q3 2017 and held it in 1 quarter.
Clearline Capital's Evolent Health position peaked at $659K in Q3 2017.
156 funds tracked by Wall St. Rank held Evolent Health as of Q4 2017.

Based on Clearline Capital's 13F filing for Q4 2017, filed 14 Feb 2018.